GlaxoSmithKline launches satellite R&D teams in search of new products

Just like NASA sends satellites to explore for new discoveries in outer space, drugmaker GlaxoSmithKline ($GSK) is sending R&D folks into new areas to look for drugs. The U.K.-based company is launching satellite innovation centers in Cambridge, MA, and San Diego, with the idea that they can mentor research partnerships while hunting down new technologies and starting biotech startups. The office in San Diego will be overseen by Damien McDevitt and include an R&D team of 5 to 10 staffers. It is the company's first R&D office in California. Story | More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.